董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mira Kirti Sahney | -- | Director | -- | 未披露 | 未持股 | 2025-07-28 |
| Kevin M. King | -- | Independent Director | -- | 24.50万美元 | 7.69 | 2025-07-28 |
| Glenn S. Boehnlein | -- | Independent Director | -- | 25.00万美元 | 7.69 | 2025-07-28 |
| Elizabeth A. Mora | -- | Chairperson of the Board | -- | 31.25万美元 | 7.92 | 2025-07-28 |
| Mary Ladone | 女 | Independent Director | -- | 25.00万美元 | 7.69 | 2025-07-28 |
| Kevin R.M. Smith | 男 | Chief Executive Officer, President and Director | 55 | 261.38万美元 | 13.35 | 2025-07-28 |
| Heather Rider | 女 | Independent Director | 66 | 24.25万美元 | 8.82 | 2025-07-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer Yi Boyer | 女 | Executive Vice President, Enterprise Enablement and Chief Human Resources Officer | 51 | 146.94万美元 | 2.67 | 2025-07-28 |
| Mary Wright | 女 | Chief Accounting Officer | 39 | 未披露 | 1.91 | 2025-07-28 |
| Michael Bourque | -- | Principal Accounting Officer and Principal Financial Officer | -- | 170.86万美元 | 9.46 | 2025-07-28 |
| Gregoire Ramade | -- | Executive Vice President and Chief Commercial Officer | -- | 141.91万美元 | 4.42 | 2025-07-28 |
| Kevin P. Smith | -- | Executive Vice President, Business Development, General Counsel and Secretary | -- | 146.30万美元 | 2.20 | 2025-07-28 |
| Kevin R.M. Smith | 男 | Chief Executive Officer, President and Director | 55 | 261.38万美元 | 13.35 | 2025-07-28 |
董事简历
中英对照 | 中文 | 英文- Mira Kirti Sahney
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Kevin M. King
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Glenn S. Boehnlein
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Elizabeth A. Mora
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mary Ladone
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Kevin R.M. Smith
-
Kevin R.M. Smith，自2023年11月起担任首席执行官、总裁和董事会成员。在加入Inogen之前，Smith先生在2017年至2019年担任美洲销售和营销执行副总裁后，于2019年4月至2023年11月在医疗器械公司Sirtex Medical Limited担任首席执行官（CEO）、总裁兼执行董事。史密斯先生还在2019年至2023年期间担任Sirtex的董事会成员。自2021年12月至2022年4月，Smith先生还在生物技术公司OncoSec医疗，Inc.（纳斯达克：ONCS）担任临时总裁兼首席执行官兼董事，并于2020年至2023年担任其董事会成员。Smith先生在之前的职位上曾担任Gel-e，Inc.业务发展执行副总裁、Sensium Healthcare首席商务官、泰利福销售和营销全球副总裁，并在其他医疗器械公司担任过各种销售和营销职务。Smith先生拥有凤凰城大学全球管理工商管理硕士学位和肯塔基大学市场营销理学学士学位。
Kevin R.M. Smith,has served as Chief Executive Officer, President and a member of Board since November 2023. Prior to joining Inogen, Mr. Smith served as the Chief Executive Officer (CEO), President and Executive Director at Sirtex Medical Limited, a medical device company, from April 2019 to November 2023, after serving as Executive Vice President of Sales and Marketing, Americas from 2017 to 2019. Mr. Smith also served on Sirtex's Board of Directors from 2019 to 2023. From December 2021 to April 2022, Mr. Smith also served as interim President and Chief Executive Officer and Director at OncoSec Medical, Inc. (Nasdaq: ONCS), a biotechnology company, and served on its Board of Directors from 2020 to 2023. In his previous roles Mr. Smith served as Executive Vice President of Business Development at Gel-e, Inc., as Chief Commercial Officer at Sensium Healthcare, as Global Vice President of Sales and Marketing at Teleflex, and served in various sales and marketing roles in other medical device companies. Mr. Smith holds a Master of Business Administration in Global Management from University of Phoenix and a Bachelor of Science in Marketing from the University of Kentucky. - Kevin R.M. Smith，自2023年11月起担任首席执行官、总裁和董事会成员。在加入Inogen之前，Smith先生在2017年至2019年担任美洲销售和营销执行副总裁后，于2019年4月至2023年11月在医疗器械公司Sirtex Medical Limited担任首席执行官（CEO）、总裁兼执行董事。史密斯先生还在2019年至2023年期间担任Sirtex的董事会成员。自2021年12月至2022年4月，Smith先生还在生物技术公司OncoSec医疗，Inc.（纳斯达克：ONCS）担任临时总裁兼首席执行官兼董事，并于2020年至2023年担任其董事会成员。Smith先生在之前的职位上曾担任Gel-e，Inc.业务发展执行副总裁、Sensium Healthcare首席商务官、泰利福销售和营销全球副总裁，并在其他医疗器械公司担任过各种销售和营销职务。Smith先生拥有凤凰城大学全球管理工商管理硕士学位和肯塔基大学市场营销理学学士学位。
- Kevin R.M. Smith,has served as Chief Executive Officer, President and a member of Board since November 2023. Prior to joining Inogen, Mr. Smith served as the Chief Executive Officer (CEO), President and Executive Director at Sirtex Medical Limited, a medical device company, from April 2019 to November 2023, after serving as Executive Vice President of Sales and Marketing, Americas from 2017 to 2019. Mr. Smith also served on Sirtex's Board of Directors from 2019 to 2023. From December 2021 to April 2022, Mr. Smith also served as interim President and Chief Executive Officer and Director at OncoSec Medical, Inc. (Nasdaq: ONCS), a biotechnology company, and served on its Board of Directors from 2020 to 2023. In his previous roles Mr. Smith served as Executive Vice President of Business Development at Gel-e, Inc., as Chief Commercial Officer at Sensium Healthcare, as Global Vice President of Sales and Marketing at Teleflex, and served in various sales and marketing roles in other medical device companies. Mr. Smith holds a Master of Business Administration in Global Management from University of Phoenix and a Bachelor of Science in Marketing from the University of Kentucky.
- Heather Rider
-
Heather Rider，自2014年起担任董事会成员，薪酬委员会主席，提名和治理委员会成员（2020年10月1日起）。从2018年1月1日至2020年9月30日，Rider女士还担任薪酬、提名和治理委员会主席。从2012年到2013年，她担任Cymer， Inc.的全球人力资源副总裁，Cymer, Inc.是一家上市的半导体制造光源供应商，于2013年被ASML Holding NV收购。从2010年10月到2012年9月，她担任Alphatec Holdings， Inc.（一家上市的医疗设备公司，专注于脊柱疾病的手术治疗）的全球人力资源高级副总裁；从2006年到2010年，她担任Intuitive surgical， Inc.（一家上市的机器人手术系统制造商）的人力资源副总裁。从2001年到2005年，她担任Sunrise Medical， Inc.（耐用医疗设备的全球制造商和分销商）的全球人力资源高级副总裁。从1998年到2001年，她担任Biosense Webster的人力资源副总裁，该公司是Johnson & Johnson家族公司的成员，也是心内导管和定位技术的医疗设备制造商。1998年之前，她曾担任City of Hope（癌症、糖尿病和其他危及生命的疾病的领先研究和治疗中心）、CAP/MPT（加州医生的医疗事故提供商和大型医生团体和医院的医疗事故保险）和Environmental Diagnostics International（生物诊断公司，专注于使用单克隆抗体技术检测环境化合物和疾病）的人力资源主管。她目前担任医疗技术公司Intricon Corporation的董事会成员。她持有Claremont McKenna College的心理学学士学位和Pepperdine大学的工商管理硕士学位。
Heather Rider has served as a Member of Board since 2014 Chairperson of the Compensation Committee and Member of the Nominating and Governance Committee since October 1 2020. Ms. Rider also served as Chairperson of the Compensation, Nominating and Governance Committee from January 1 2018 to September 30 2020. From 2012 to 2013 Ms. Rider served as Vice President, Global Human Resources of Cymer, Inc., a publicly traded supplier of light sources for semiconductor manufacturing that was acquired by ASML Holding NV in 2013. From October 2010 to September 2012 Ms. Rider served as Senior Vice President, Global Human Resources of Alphatec Holdings, Inc., a publicly-traded medical device company focused on surgical treatment of spine disorders, and from 2006 to 2010 she served as Vice President, Human Resources of Intuitive Surgical, Inc., a publicly-traded manufacturer of robotic surgical systems. From 2001 to 2005 Ms. Rider served as Senior Vice President of Global Human Resources of Sunrise Medical, Inc., a global manufacturer and distributor of durable medical equipment. From 1998 to 2001 Ms. Rider served as Vice President of Human Resources of Biosense Webster, a member of the Johnson & Johnson family of companies, and a medical device manufacturer of intracardiac catheters and location technology. Prior to 1998 Ms. Rider served as Head of Human Resources for City of Hope, a leading research and treatment center for cancer, diabetes and other life-threatening diseases, CAP/MPT, a medical malpractice provider for physicians in California and medical malpractice insurance for large physician groups and hospitals, and Environmental Diagnostics International, a bio-diagnostics company with focus on the detection of environmental compounds and diseases using monoclonal antibody technology. Ms. Rider currently serves on the Board of Directors of Intricon Corporation, a medical technology company. Ms. Rider holds a Bachelor of Arts in Psychology from Claremont McKenna College and an M.B.A. from Pepperdine University. - Heather Rider，自2014年起担任董事会成员，薪酬委员会主席，提名和治理委员会成员（2020年10月1日起）。从2018年1月1日至2020年9月30日，Rider女士还担任薪酬、提名和治理委员会主席。从2012年到2013年，她担任Cymer， Inc.的全球人力资源副总裁，Cymer, Inc.是一家上市的半导体制造光源供应商，于2013年被ASML Holding NV收购。从2010年10月到2012年9月，她担任Alphatec Holdings， Inc.（一家上市的医疗设备公司，专注于脊柱疾病的手术治疗）的全球人力资源高级副总裁；从2006年到2010年，她担任Intuitive surgical， Inc.（一家上市的机器人手术系统制造商）的人力资源副总裁。从2001年到2005年，她担任Sunrise Medical， Inc.（耐用医疗设备的全球制造商和分销商）的全球人力资源高级副总裁。从1998年到2001年，她担任Biosense Webster的人力资源副总裁，该公司是Johnson & Johnson家族公司的成员，也是心内导管和定位技术的医疗设备制造商。1998年之前，她曾担任City of Hope（癌症、糖尿病和其他危及生命的疾病的领先研究和治疗中心）、CAP/MPT（加州医生的医疗事故提供商和大型医生团体和医院的医疗事故保险）和Environmental Diagnostics International（生物诊断公司，专注于使用单克隆抗体技术检测环境化合物和疾病）的人力资源主管。她目前担任医疗技术公司Intricon Corporation的董事会成员。她持有Claremont McKenna College的心理学学士学位和Pepperdine大学的工商管理硕士学位。
- Heather Rider has served as a Member of Board since 2014 Chairperson of the Compensation Committee and Member of the Nominating and Governance Committee since October 1 2020. Ms. Rider also served as Chairperson of the Compensation, Nominating and Governance Committee from January 1 2018 to September 30 2020. From 2012 to 2013 Ms. Rider served as Vice President, Global Human Resources of Cymer, Inc., a publicly traded supplier of light sources for semiconductor manufacturing that was acquired by ASML Holding NV in 2013. From October 2010 to September 2012 Ms. Rider served as Senior Vice President, Global Human Resources of Alphatec Holdings, Inc., a publicly-traded medical device company focused on surgical treatment of spine disorders, and from 2006 to 2010 she served as Vice President, Human Resources of Intuitive Surgical, Inc., a publicly-traded manufacturer of robotic surgical systems. From 2001 to 2005 Ms. Rider served as Senior Vice President of Global Human Resources of Sunrise Medical, Inc., a global manufacturer and distributor of durable medical equipment. From 1998 to 2001 Ms. Rider served as Vice President of Human Resources of Biosense Webster, a member of the Johnson & Johnson family of companies, and a medical device manufacturer of intracardiac catheters and location technology. Prior to 1998 Ms. Rider served as Head of Human Resources for City of Hope, a leading research and treatment center for cancer, diabetes and other life-threatening diseases, CAP/MPT, a medical malpractice provider for physicians in California and medical malpractice insurance for large physician groups and hospitals, and Environmental Diagnostics International, a bio-diagnostics company with focus on the detection of environmental compounds and diseases using monoclonal antibody technology. Ms. Rider currently serves on the Board of Directors of Intricon Corporation, a medical technology company. Ms. Rider holds a Bachelor of Arts in Psychology from Claremont McKenna College and an M.B.A. from Pepperdine University.
高管简历
中英对照 | 中文 | 英文- Jennifer Yi Boyer
Jennifer Yi Boyer，拥有29年的战略和转型领导经验，在人才获取、人才发展、组织有效性、转型领导力、DEI（多元化、公平和包容）、战略规划、高管发展和员工队伍规划等领域拥有深厚的专业知识。她自2025年5月起担任公司执行副总裁、企业赋能和首席人力资源官。Yi Boyer女士于2022年2月加入Inogen，担任首席人力资源官，内部升任现职。在加入Inogen之前，Yi Boyer女士于2021年1月至2022年2月期间在Fiscal Note担任首席人事官兼多元化、公平和包容性高级副总裁。她还曾于2011年8月至2020年10月担任ACT首席人才官，于2008年10月至2011年8月担任Diversey，Inc.人才战略副总裁，于2006年5月至2008年10月担任CIT Group人才发展副总裁，并于1996年6月至2006年5月担任多个跨行业的其他人力资源和质量管理职务。Yi Boyer女士毕业于康奈尔大学，在那里她获得了酒店管理理学学士学位，并且毕业于Seton Hall大学，在那里她获得了硕士学位，战略传播和领导力。她还在哈佛大学肯尼迪政府学院完成了行政领导证书。
Jennifer Yi Boyer,has 29 years of strategic and transformational leadership experience with deep expertise in the areas of Talent Acquisition, Talent Development, Organization Effectiveness, Transformational Leadership, DEI (Diversity, Equity & Inclusion), Strategic Planning, Executive Development, and workforce planning. She has served as Executive Vice President, Enterprise Enablement and Chief Human Resources Officer of the Company since May 2025. Ms. Yi Boyer joined Inogen in February 2022 as Chief Human Resources Officer and has risen internally to her current role. Prior to joining Inogen, Ms. Yi Boyer served as Chief People Officer and Senior Vice President of Diversity, Equity and Inclusion at Fiscal Note from January 2021 to February 2022. She also held the positions of Chief Talent Officer at ACT from August 2011 to October 2020, Vice President Talent Strategies at Diversey, Inc. from October 2008 to August 2011, Vice President of Talent Development at CIT Group from May 2006 to October 2008, and in various other human resources and quality management roles across various industries from June 1996 to May 2006. Ms. Yi Boyer is a graduate of Cornell University, where she earned her Bachelor of Science, Hotel Administration and is a graduate of Seton Hall University, where she earned her Masters, Strategic Communication and Leadership. She also completed an executive leadership certificate at the JFK School of Government at Harvard University.- Jennifer Yi Boyer，拥有29年的战略和转型领导经验，在人才获取、人才发展、组织有效性、转型领导力、DEI（多元化、公平和包容）、战略规划、高管发展和员工队伍规划等领域拥有深厚的专业知识。她自2025年5月起担任公司执行副总裁、企业赋能和首席人力资源官。Yi Boyer女士于2022年2月加入Inogen，担任首席人力资源官，内部升任现职。在加入Inogen之前，Yi Boyer女士于2021年1月至2022年2月期间在Fiscal Note担任首席人事官兼多元化、公平和包容性高级副总裁。她还曾于2011年8月至2020年10月担任ACT首席人才官，于2008年10月至2011年8月担任Diversey，Inc.人才战略副总裁，于2006年5月至2008年10月担任CIT Group人才发展副总裁，并于1996年6月至2006年5月担任多个跨行业的其他人力资源和质量管理职务。Yi Boyer女士毕业于康奈尔大学，在那里她获得了酒店管理理学学士学位，并且毕业于Seton Hall大学，在那里她获得了硕士学位，战略传播和领导力。她还在哈佛大学肯尼迪政府学院完成了行政领导证书。
- Jennifer Yi Boyer,has 29 years of strategic and transformational leadership experience with deep expertise in the areas of Talent Acquisition, Talent Development, Organization Effectiveness, Transformational Leadership, DEI (Diversity, Equity & Inclusion), Strategic Planning, Executive Development, and workforce planning. She has served as Executive Vice President, Enterprise Enablement and Chief Human Resources Officer of the Company since May 2025. Ms. Yi Boyer joined Inogen in February 2022 as Chief Human Resources Officer and has risen internally to her current role. Prior to joining Inogen, Ms. Yi Boyer served as Chief People Officer and Senior Vice President of Diversity, Equity and Inclusion at Fiscal Note from January 2021 to February 2022. She also held the positions of Chief Talent Officer at ACT from August 2011 to October 2020, Vice President Talent Strategies at Diversey, Inc. from October 2008 to August 2011, Vice President of Talent Development at CIT Group from May 2006 to October 2008, and in various other human resources and quality management roles across various industries from June 1996 to May 2006. Ms. Yi Boyer is a graduate of Cornell University, where she earned her Bachelor of Science, Hotel Administration and is a graduate of Seton Hall University, where she earned her Masters, Strategic Communication and Leadership. She also completed an executive leadership certificate at the JFK School of Government at Harvard University.
- Mary Wright
Mary Wright，拥有17年的会计和财务领导经验。最近，Wright女士从2024年10月起担任公司副总裁/公司财务总监，并从2022年7月起担任技术会计和财务报告副总裁。她于2015年5月加入Inogen，目前内部升任现职。在加入Inogen之前，Wright女士曾在德勤会计师事务所（Deloitte & Touche LLP）担任过不同的高级职务。Wright女士毕业于俄亥俄大学，在那里她获得了工商管理、会计和国际商务学士学位，她是美国注册会计师协会（AICPA）的成员。
Mary Wright,has 17 years of accounting and financial leadership experience. Most recently, Ms. Wright served as Vice President/Corporate Controller, Accounting of the Company from October 2024 and Vice President, Technical Accounting & Financial Reporting from July 2022. She joined Inogen in May 2015 and has risen internally to her current role. Prior to joining Inogen, Ms. Wright served in various roles of increasing seniority at Deloitte & Touche LLP. Ms. Wright is a graduate of Ohio University, where she earned her Bachelor of Business Administration, Accounting and International Business, and she is a member of the American Institute of Certified Public Accountants (AICPA).- Mary Wright，拥有17年的会计和财务领导经验。最近，Wright女士从2024年10月起担任公司副总裁/公司财务总监，并从2022年7月起担任技术会计和财务报告副总裁。她于2015年5月加入Inogen，目前内部升任现职。在加入Inogen之前，Wright女士曾在德勤会计师事务所（Deloitte & Touche LLP）担任过不同的高级职务。Wright女士毕业于俄亥俄大学，在那里她获得了工商管理、会计和国际商务学士学位，她是美国注册会计师协会（AICPA）的成员。
- Mary Wright,has 17 years of accounting and financial leadership experience. Most recently, Ms. Wright served as Vice President/Corporate Controller, Accounting of the Company from October 2024 and Vice President, Technical Accounting & Financial Reporting from July 2022. She joined Inogen in May 2015 and has risen internally to her current role. Prior to joining Inogen, Ms. Wright served in various roles of increasing seniority at Deloitte & Touche LLP. Ms. Wright is a graduate of Ohio University, where she earned her Bachelor of Business Administration, Accounting and International Business, and she is a member of the American Institute of Certified Public Accountants (AICPA).
- Michael Bourque
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Gregoire Ramade
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Kevin P. Smith
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Kevin R.M. Smith
Kevin R.M. Smith，自2023年11月起担任首席执行官、总裁和董事会成员。在加入Inogen之前，Smith先生在2017年至2019年担任美洲销售和营销执行副总裁后，于2019年4月至2023年11月在医疗器械公司Sirtex Medical Limited担任首席执行官（CEO）、总裁兼执行董事。史密斯先生还在2019年至2023年期间担任Sirtex的董事会成员。自2021年12月至2022年4月，Smith先生还在生物技术公司OncoSec医疗，Inc.（纳斯达克：ONCS）担任临时总裁兼首席执行官兼董事，并于2020年至2023年担任其董事会成员。Smith先生在之前的职位上曾担任Gel-e，Inc.业务发展执行副总裁、Sensium Healthcare首席商务官、泰利福销售和营销全球副总裁，并在其他医疗器械公司担任过各种销售和营销职务。Smith先生拥有凤凰城大学全球管理工商管理硕士学位和肯塔基大学市场营销理学学士学位。
Kevin R.M. Smith,has served as Chief Executive Officer, President and a member of Board since November 2023. Prior to joining Inogen, Mr. Smith served as the Chief Executive Officer (CEO), President and Executive Director at Sirtex Medical Limited, a medical device company, from April 2019 to November 2023, after serving as Executive Vice President of Sales and Marketing, Americas from 2017 to 2019. Mr. Smith also served on Sirtex's Board of Directors from 2019 to 2023. From December 2021 to April 2022, Mr. Smith also served as interim President and Chief Executive Officer and Director at OncoSec Medical, Inc. (Nasdaq: ONCS), a biotechnology company, and served on its Board of Directors from 2020 to 2023. In his previous roles Mr. Smith served as Executive Vice President of Business Development at Gel-e, Inc., as Chief Commercial Officer at Sensium Healthcare, as Global Vice President of Sales and Marketing at Teleflex, and served in various sales and marketing roles in other medical device companies. Mr. Smith holds a Master of Business Administration in Global Management from University of Phoenix and a Bachelor of Science in Marketing from the University of Kentucky.- Kevin R.M. Smith，自2023年11月起担任首席执行官、总裁和董事会成员。在加入Inogen之前，Smith先生在2017年至2019年担任美洲销售和营销执行副总裁后，于2019年4月至2023年11月在医疗器械公司Sirtex Medical Limited担任首席执行官（CEO）、总裁兼执行董事。史密斯先生还在2019年至2023年期间担任Sirtex的董事会成员。自2021年12月至2022年4月，Smith先生还在生物技术公司OncoSec医疗，Inc.（纳斯达克：ONCS）担任临时总裁兼首席执行官兼董事，并于2020年至2023年担任其董事会成员。Smith先生在之前的职位上曾担任Gel-e，Inc.业务发展执行副总裁、Sensium Healthcare首席商务官、泰利福销售和营销全球副总裁，并在其他医疗器械公司担任过各种销售和营销职务。Smith先生拥有凤凰城大学全球管理工商管理硕士学位和肯塔基大学市场营销理学学士学位。
- Kevin R.M. Smith,has served as Chief Executive Officer, President and a member of Board since November 2023. Prior to joining Inogen, Mr. Smith served as the Chief Executive Officer (CEO), President and Executive Director at Sirtex Medical Limited, a medical device company, from April 2019 to November 2023, after serving as Executive Vice President of Sales and Marketing, Americas from 2017 to 2019. Mr. Smith also served on Sirtex's Board of Directors from 2019 to 2023. From December 2021 to April 2022, Mr. Smith also served as interim President and Chief Executive Officer and Director at OncoSec Medical, Inc. (Nasdaq: ONCS), a biotechnology company, and served on its Board of Directors from 2020 to 2023. In his previous roles Mr. Smith served as Executive Vice President of Business Development at Gel-e, Inc., as Chief Commercial Officer at Sensium Healthcare, as Global Vice President of Sales and Marketing at Teleflex, and served in various sales and marketing roles in other medical device companies. Mr. Smith holds a Master of Business Administration in Global Management from University of Phoenix and a Bachelor of Science in Marketing from the University of Kentucky.